Vita Therapeutics is a biotechnology startup founded in 2018 in the United States. The company aims to advance treatments in multiple indications through its cell therapy platform. With a mission to utilize the power of genetics, Vita Therapeutics is focused on delivering life-transformative cell therapies by unlocking the potential of engineered cellular medicine.
In its most recent funding round, Vita Therapeutics secured a significant $31.00M Series B investment on 12 October 2022. The investment was led by prominent investors including TEDCO, Cambrian Biopharma, Riptide Ventures, Cedars Sinai, and Solve FSHD.
With its innovative approach and strong investor backing, Vita Therapeutics is well-positioned to make a noteworthy impact in the biotechnology sector, offering potential opportunities for venture capital firms seeking promising investments in the field of cellular medicine.
